The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of ...

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly ...

While announcing billions of dollars in new U.S. investments, David Ricks called for an extension of 2017 tax cuts and ...

Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida ...

The meeting, which helps the FDA give guidance to vaccine makers on which flu strains to target, is the second to be ...

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...

Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

"Any place that gets cut, it's going to have an impact, because there's not any spare personnel at FDA,” said former agency ...

Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...